6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Donor sex, age and ethnicity impact stored red blood cell antioxidant metabolism through mechanisms in part explained by glucose 6-phosphate dehydrogenase levels and activity

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Red blood cell (RBC) storage in the blood bank promotes the progressive accumulation of metabolic alterations that may ultimately impact the erythrocyte capacity to cope with oxidant stressors. However, the metabolic underpinnings of the capacity of RBC to resist oxidant stress and the potential impact of donor biology on this phenotype are not known. Within the framework of the REDS-III RBC-Omics study, RBC from 8,502 healthy blood donors were stored for 42 days and tested for their propensity to hemolyse following oxidant stress. A subset of extreme hemolysers donated a second unit of blood, which was stored for 10, 23, and 42 days and profiled again for oxidative hemolysis and metabolomics (599 samples). Alterations of RBC energy and redox homeostasis were noted in donors with high oxidative hemolysis. RBC from females, donors over 60 years old, donors of Asian/South Asian race-ethnicity, and RBC stored in additive solution- 3 were each independently characterized by improved antioxidant metabolism compared to, respectively, males, donors under 30 years old, Hispanic and African American race ethnicity donors, and RBC stored in additive solution-1. Merging metabolomics data with results from an independent genome-wide association study on the same cohort, we identified metabolic markers of hemolysis and glucose 6-phosphate dehydrogenasedeficiency, which were associated with extremes in oxidative hemolysis and dysregulation in nicotinamide adenine dinucleotide phosphate and glutathione- dependent detoxification pathways of oxidized lipids. Donor sex, age, ethnicity, additive solution and glucose 6-phosphate dehydrogenase status impact the metabolism of the stored erythrocyte and its susceptibility to hemolysis following oxidative insults.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Chronic interleukin-1 drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal

          Haematopoietic stem cells (HSC) maintain lifelong blood production and increase blood cell numbers in response to chronic and acute injury. However, the mechanism(s) by which inflammatory insults are communicated to HSCs and their consequences for HSC activity remain largely unknown. Here, we demonstrate that interleukin-1 (IL-1), which functions as a key pro-inflammatory ‘emergency’ signal, directly accelerates cell division and myeloid differentiation of HSCs via precocious activation of a PU.1-dependent gene program. While this effect is essential for rapid myeloid recovery following acute injury to the bone marrow (BM), chronic IL-1 exposure restricts HSC lineage output, severely erodes HSC self-renewal capacity, and primes IL-1-exposed HSCs to fail massive replicative challenges like transplantation. Importantly, these damaging effects are transient and fully reversible upon IL-1 withdrawal. Our results identify a critical regulatory circuit that tailors HSC responses to acute needs, and likely underlies deregulated blood homeostasis in chronic inflammation conditions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Red blood cell storage lesion: causes and potential clinical consequences

            Red blood cells (RBCs) are a specialised organ that enabled the evolution of multicellular organisms by supplying a sufficient quantity of oxygen to cells that cannot obtain oxygen directly from ambient air via diffusion, thereby fueling oxidative phosphorylation for highly efficient energy production. RBCs have evolved to optimally serve this purpose by packing high concentrations of haemoglobin in their cytosol and shedding nuclei and other organelles. During their circulatory lifetimes in humans of approximately 120 days, RBCs are poised to transport oxygen by metabolic/redox enzymes until they accumulate damage and are promptly removed by the reticuloendothelial system. These elaborate evolutionary adaptions, however, are no longer effective when RBCs are removed from the circulation and stored hypothermically in blood banks, where they develop storage-induced damages (“storage lesions”) that accumulate over the shelf life of stored RBCs. This review attempts to provide a comprehensive view of the literature on the subject of RBC storage lesions and their purported clinical consequences by incorporating the recent exponential growth in available data obtained from “omics” technologies in addition to that published in more traditional literature. To summarise this vast amount of information, the subject is organised in figures with four panels: i) root causes; ii) RBC storage lesions; iii) physiological effects; and iv) reported outcomes. The driving forces for the development of the storage lesions can be roughly classified into two root causes: i) metabolite accumulation/depletion, the target of various interventions (additive solutions) developed since the inception of blood banking; and ii) oxidative damages, which have been reported for decades but not addressed systemically until recently. Downstream physiological consequences of these storage lesions, derived mainly by in vitro studies, are described, and further potential links to clinical consequences are discussed. Interventions to postpone the onset and mitigate the extent of the storage lesion development are briefly reviewed. In addition, we briefly discuss the results from recent randomised controlled trials on the age of stored blood and clinical outcomes of transfusion.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              An update on red blood cell storage lesions, as gleaned through biochemistry and omics technologies.

              Red blood cell (RBC) aging in the blood bank is characterized by the accumulation of a significant number of biochemical and morphologic alterations. Recent mass spectrometry and electron microscopy studies have provided novel insights into the molecular changes underpinning the accumulation of storage lesions to RBCs in the blood bank. Biochemical lesions include altered cation homeostasis, reprogrammed energy, and redox metabolism, which result in the impairment of enzymatic activity and progressive depletion of high-energy phosphate compounds. These factors contribute to the progressive accumulation of oxidative stress, which in turn promotes oxidative lesions to proteins (carbonylation, fragmentation, hemoglobin glycation) and lipids (peroxidation). Biochemical lesions negatively affect RBC morphology, which is marked by progressive membrane blebbing and vesiculation. These storage lesions contribute to the altered physiology of long-stored RBCs and promote the rapid clearance of up to one-fourth of long-stored RBCs from the recipient's bloodstream after 24 hours from administration. While prospective clinical evidence is accumulating, from the present review it emerges that biochemical, morphologic, and omics profiles of stored RBCs have observable changes after approximately 14 days of storage. Future studies will assess whether these in vitro observations might have clinically meaningful effects.
                Bookmark

                Author and article information

                Contributors
                Role: for the Recipient Epidemiology and Donor Evaluation Study-III (REDS III)
                Role: for the Recipient Epidemiology and Donor Evaluation Study-III (REDS III)
                Journal
                Haematologica
                Haematologica
                HAEMA
                Haematologica
                Fondazione Ferrata Storti
                0390-6078
                1592-8721
                02 April 2020
                01 May 2021
                : 106
                : 5
                : 1290-1302
                Affiliations
                [1 ]Department of Biochemistry and Molecular Genetics, University of Colorado Denver – Anschutz Medical Campus , Aurora, CO, USA
                [2 ]Department of Medicine – Division of Hematology, University of Colorado Denver – Anschutz Medical Campus , Aurora, CO, USA
                [3 ]Vitalant Research Institute (previously Blood Systems Research Institute), Denver, CO, USA
                [4 ]Bloodworks Northwest Research Institute , Seattle, WA, USA
                [5 ]University of Pittsburgh , Pittsburgh, PA, USA
                [6 ]RTI International , Atlanta, GA, USA
                [7 ]University of British Columbia , Victoria, Canada
                [8 ]Vitalant Research Institute (previously Blood Systems Research Institute) , San Francisco, CA, USA
                [9 ]University of Virginia , Charlotesville, VA, USA
                Author notes
                #MPB and JCZ contributed equally as co-senior authors

                RBC-Omics study group members

                The NHLBI Recipient Epidemiology Donor Evaluation Study- III (REDS-III), Red Blood Cell (RBC)-Omics study, is the responsibility of the following persons: Hubs: AE Mast, JL Gottschall, WB, LA, JM, AH, ZU, and VJ, BloodCenter of Wisconsin, Milwaukee, WI, USA; DJT, JEK and PAD’A, The Institute for Transfusion Medicine (ITXM), Pittsburgh, PA, USA; E. L. Murphy and AMG, University of California, San Francisco, San Francisco, CA, USA; RGC, BRS, and STJ; American Red Cross Blood Services, Farmington, CT, USA; Data coordinating center: DJB, MTS, SME, GPP, YG, NH, DR, and BCS; RTI International, Rockville, MD, USA; Central and testing laboratories: MPB, MCL, MS, and SK, Blood Systems Research Institute, San Francisco, CA, USA; TK and MG, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Steering committee chairman: SHK, University of British Columbia, Victoria, BC, Canada; National Heart, Lung, and Blood Institute, National Institutes of Health: SAG, KBM and AMC.

                Disclosures

                Though unrelated to the contents of this manuscripts, the authors declare that AD is a founder of Omix Technologies Inc and Altis Biosciencens LLC. James C Zimring serves as a consultant for Rubius Therapeutics. All the other authors disclose no conflicts of interest relevant to this study. Angelo D’Alessandro is a consultant for Hemanext Inc. James C Zimring serves on the scientific advisory board for Rubius Therapeutics. All the other authors disclose no conflicts of interest relevant to this study.

                Contributions

                TK, SK, MTG, ML, MS, MPB, GP, JCZ designed the study. AD, XF, JAR, RCH, JCZ performed metabolomics analyses; YG, GP performed genomics analyses; TK performed oxidative hemolysis measurements; AD prepared figures and wrote the first version of the manuscript. All the authors contributed to the finalization of the manuscript.

                Article
                10.3324/haematol.2020.246603
                8094095
                32241843
                39c104b9-5304-498f-89a5-c0653087ee0d
                Copyright© 2021 Ferrata Storti Foundation

                This article is distributed under the terms of the Creative Commons Attribution Noncommercial License ( by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

                History
                : 07 January 2020
                : 27 March 2020
                Page count
                Figures: 7, Tables: 0, Equations: 0, References: 50, Pages: 13
                Funding
                Funding Research reported in this publication was funded by the NHLBI Recipient Epidemiology and Donor Evaluation Study- III (REDS-III), which was supported by NHLBI contracts NHLBI HHSN2682011-00001I, -00002I, -00003I, - 00004I, 00005I, -00006I, -00007I, -00008I, and -00009I, as well as funds from the the National Institute of General and Medical Sciences (RM1GM131968 to ADA), NHLBI R01HL146442 and R01HL149714 (ADA), R01HL148151 (ADA, JCZ), the Boettcher Webb-Waring Investigator Award (ADA) and a Shared Instrument grant by the National Institute of Health (S10OD021641).
                Categories
                Article

                Comments

                Comment on this article